Valuation: Incyte Corporation

Market Cap 24.81B 22.48B 20.79B 18.76B 35.35B 2,339B 36.6B 250B 99.04B 1,249B 93.09B 91.12B 3,966B P/E 2026 *
58.3x
P/E 2027 * 17.3x
Enterprise Value 20.51B 18.59B 17.19B 15.51B 29.23B 1,934B 30.26B 207B 81.9B 1,033B 76.98B 75.35B 3,280B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.01x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week+1.10%
Current month+0.48%
1 month+11.37%
3 months+0.37%
6 months+22.41%
Current year+22.48%
1 week 117.84
Extreme 117.84
123.9
1 month 107.83
Extreme 107.83
123.96
Current year 89.25
Extreme 89.25
132.6
1 year 89.25
Extreme 89.25
132.6
3 years 50.35
Extreme 50.3498
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Sell

Principal Accounting Officer

-610 0.0003%
15/10/26 Exercice

Chairperson

7,926 0.0039%
1/10/26 Tax

EVP, Head of Incyte Intl

-463 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+1.10%+14.76%+127.73% 24.81B
+1.26%+6.61%+41.12%+135.59% 1,271B
+0.79%+3.45%+46.35%+93.56% 683B
+0.20%+1.28%+27.01%+112.80% 520B
-0.44%+3.32%+39.36%+70.94% 389B
+0.55%+0.70%+59.00%+44.20% 362B
-0.12%-0.04%+28.04%+59.86% 304B
+0.37%-0.43%+3.43%+38.57% 286B
-0.30%+1.14%+38.59%+74.61% 253B
+0.08%+0.71%+34.25%+124.32% 208B
Average +0.14%+1.51%+33.19%+88.22% 430B
Weighted average by Cap. +0.50%+2.66%+37.53%+96.65%

Financials

2026 *2027 *
Net sales 6.05B 5.49B 5.07B 4.58B 8.63B 571B 8.93B 60.95B 24.17B 305B 22.72B 22.23B 968B 6.31B 5.72B 5.29B 4.77B 8.99B 595B 9.31B 63.52B 25.19B 318B 23.68B 23.17B 1,009B
Net income 432M 392M 362M 327M 616M 40.76B 638M 4.35B 1.73B 21.77B 1.62B 1.59B 69.11B 1.45B 1.32B 1.22B 1.1B 2.07B 137B 2.15B 14.65B 5.81B 73.27B 5.46B 5.34B 233B
Net Debt -4.29B -3.89B -3.6B -3.25B -6.12B -405B -6.33B -43.23B -17.14B -216B -16.11B -15.77B -686B -5.82B -5.27B -4.88B -4.4B -8.29B -549B -8.59B -58.6B -23.23B -293B -21.84B -21.38B -930B
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
14/11/26 USD 120.97 -0.60% 950,394
12/11/26 USD 121.70 -0.47% 1,008,920
11/11/26 USD 122.27 +1.64% 1,187,539
10/11/26 USD 120.30 -1.30% 1,797,816
09/11/26 USD 121.89 +1.87% 1,154,647
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
121.70USD
Average target price
131.50USD
Spread / Average Target
+8.05%
  1. Stock Market
  2. Stocks
  3. INCY Stock